Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Interfant 06 : International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukaemia (Other IDs: CDR0000570260, DCOG-INTERFANT-06, EudraCT 2005-004599-19, CCLG-LK-2006-10).

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

UnknownPhase Unknown

0-1Age 0-1

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Lymphoblastic Lymphoma

Trial Overview Read MoreRead more

This trial is studying how well different therapies work in treating infants with newly diagnosed acute leukemia.
 

This trial is treating patients with Acute Lymphoblastic Leukaemia .

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukaemia (Other IDs: CDR0000570260, DCOG-INTERFANT-06, EudraCT 2005-004599-19, CCLG-LK-2006-10).

Cooperative Group

Dutch Childhood Oncology Group

Summary

Infant acute lymphoblastic leukaemia (ALL) is a rare disease and comprises about 4% of childhood ALL. Whereas the outcome of older children with ALL has improved to 80-85% event-free survival (EFS) infants with ALL have a worse prognosis.In 1999, a large international collaborative study group was started to develop common treatment protocols for infant ALL to try to improve the outcome for these very young children.The primary aim of the study is to assess the role of early intensification of two acute myeloid leukemia induction blocks versus standard IB protocol directly after induction, in a randomised way in MR and HR patients.The secondary aims of the study are:to assess the overall outcome of the Interfant-06 protocol compared to the historical control series, especially the Interfant-99, to assess the outcome of LR, MR and HR patients as compared to the historical control series in Interfant99, to study which factors have independent prognostic value and to assess the role of stem cell transplant (SCT) in HR patients.

Recruiting Hospitals Read MoreRead more

Monash Children's Cancer Centre
Clayton
Dr Narmatha Kuru
CCCclinicaltrials@monashhealth.org

Royal Childrens Hospital
Parkville
Trial Coordinator
CCC.ClinicalTrials@rch.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next